Symlin “Approvable” Letter Will Be Addressed By Ongoing Trials, Amylin Says
Amylin hopes that data from two ongoing open-label Symlin trials will address questions outlined by FDA in an "approvable" letter for the diabetes agent
Amylin hopes that data from two ongoing open-label Symlin trials will address questions outlined by FDA in an "approvable" letter for the diabetes agent